Trial Outcomes & Findings for Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center) (NCT NCT04025125)

NCT ID: NCT04025125

Last Updated: 2025-08-01

Results Overview

A binary variable, with 'yes' defined if there is documented evidence that a ambulatory visit was made with a cardiologist after becoming eligible by CVD risk score, and 'no' otherwise. Patients were followed from the date when they met eligibility criteria to the date of first encounter with a cardiology specialist or through a maximum of 5 years from their eligibility date. Follow-up was censored early at the end of data collection (December 31, 2020), or 6 months after the patient's last ambulatory visit, if earlier.

Recruitment status

COMPLETED

Target enrollment

2039 participants

Primary outcome timeframe

5 years

Results posted on

2025-08-01

Participant Flow

retrospective data study

As is pre-specified in the study protocol, Aim 3 data are not reported here.

Participant milestones

Participant milestones
Measure
Overall
cohort who have new elevated Cardiovascular Disease (CVD) risk
Overall Study
STARTED
2039
Overall Study
COMPLETED
2039
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

1001 participants had data or were eligible for ASCVD analysis scoring.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall
n=2039 Participants
Overall cohort.
Age, Continuous
45 years
n=2039 Participants
Sex: Female, Male
Female
1061 Participants
n=2039 Participants
Sex: Female, Male
Male
978 Participants
n=2039 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
225 Participants
n=2039 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1810 Participants
n=2039 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
n=2039 Participants
Race (NIH/OMB)
American Indian or Alaska Native
9 Participants
n=2039 Participants
Race (NIH/OMB)
Asian
35 Participants
n=2039 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=2039 Participants
Race (NIH/OMB)
Black or African American
1755 Participants
n=2039 Participants
Race (NIH/OMB)
White
65 Participants
n=2039 Participants
Race (NIH/OMB)
More than one race
11 Participants
n=2039 Participants
Race (NIH/OMB)
Unknown or Not Reported
164 Participants
n=2039 Participants
Region of Enrollment
United States
2039 Participants
n=2039 Participants
Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score
5.1 10-year risk percentage
n=1001 Participants • 1001 participants had data or were eligible for ASCVD analysis scoring.

PRIMARY outcome

Timeframe: 5 years

A binary variable, with 'yes' defined if there is documented evidence that a ambulatory visit was made with a cardiologist after becoming eligible by CVD risk score, and 'no' otherwise. Patients were followed from the date when they met eligibility criteria to the date of first encounter with a cardiology specialist or through a maximum of 5 years from their eligibility date. Follow-up was censored early at the end of data collection (December 31, 2020), or 6 months after the patient's last ambulatory visit, if earlier.

Outcome measures

Outcome measures
Measure
Overall
n=2039 Participants
cohort who have new elevated CVD risk
Number of Participants With Visit to a Cardiology Specialist From Cohort
283 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 years

Incidence of all-cause death will be determined from electronic health record data and a query of the National Death Index.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 years

Incidence of first stroke event will be determined from diagnosis and/or procedure codes from electronic health record data.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 5 years

Incidence of first major adverse cardiovascular event (composite of cardiovascular death and myocardial infarction) will be determined from diagnosis and/or procedure codes from electronic health record data and a query of the National Death Index (Plus).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Approximately 60 minutes

Qualitative information will be assessed from semi-structured interviews conducted with participating healthcare providers

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Approximately 60 minutes

Qualitative information will be assessed from semi-structured interviews conducted with participating patients

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Longitudinal evaluation during 5 years of follow up.

Cholesterol control will be defined based on prevailing guidelines during the study period and will be evaluated based on cholesterol laboratory measures recorded in electronic health record data.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Longitudinal evaluation during 5 years of follow up.

Blood pressure control will be defined based on prevailing guidelines during the study period (blood pressure \<140/90 mmHg) and will be evaluated based on blood pressures recorded in electronic health record data.

Outcome measures

Outcome data not reported

Adverse Events

Overall

Serious events: 0 serious events
Other events: 0 other events
Deaths: 137 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Gerald Bloomfield

Duke University

Phone: 919-668-8702

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place